Skip to Main Content

Paper Details

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.
Cancer Res
233
2015

Datasets

Release 1.2